• Mean time to graft reduced to 13.6 days vs. 33.2 days real-world benchmark (~20 day reduction)
• Median time to graft of 11 days, with grafting as early as 5 days
• Study ongoing with full dataset expected in 2026

AVITA Medical, Inc. announced positive interim results from its Cohealyx-I multi-center study, demonstrating a reduction of nearly 20 days in mean time to skin grafting (13.6 days vs 33.2 days benchmark) for patients with full-thickness wounds. The interim analysis of 40 patients showed a median time to grafting of 11 days, with grafting achieved as early as 5 days. Investigators reported 90% satisfaction at the time of grafting, including among predominantly first-time users, supporting consistent performance and potential for broader adoption in clinical practice. The data will be presented at an AVITA Medical symposium during the American Burn Association Annual Meeting. AVITA Medical will also host a KOL webinar to review the data and case studies. Cohealyx is a collagen-based dermal matrix designed to support vascularization and optimize the wound bed for closure, and is intended for use in staged surgical procedures for acute full-thickness wounds.

The study is ongoing, with the full dataset expected in 2026. AVITA Medical believes the meaningful reduction in time to grafting and high investigator satisfaction highlight Cohealyx's potential as a differentiated solution with the ability to drive broader adoption as the company works to improve each stage of the wound healing pathway.